Hervycta Plus 440mg Injection: Effective Medication for Your Needs

Active constituent: Trastuzumab

Indications:

• Advanced and metastatic breast cancer in HER2-positive patients.
• Metastatic gastric cancer with increased levels of HER2 proteins.

Mechanism of action:

• Targeted therapy for HER2-positive breast cancer.
• Selectively binds to HER2 proteins, stopping the growth of cancer cells.

Administration:

• Administered intravenously.
• Initial infusion time is 90 minutes; subsequent doses may be administered within 30 minutes if well tolerated.

Contraindications:

• Not recommended for patients under 18 years of age.
• Contraindicated for patients with severe breathing problems or those requiring oxygen treatment.
• Inform your physician if you have any heart problems, breathlessness, or previous cancer treatment.

Safety advice:

• Pregnancy: discuss with your physician before taking.
• Breastfeeding: avoid breastfeeding during treatment and for at least 7 months after the final dose.
• Lungs: consult your doctor if you have any lung conditions before starting treatment.
• Liver: inform your physician if you have any liver disorders.
• Alcohol: consult your doctor to know if it is safe to consume alcohol while on treatment.
• Driving: avoid driving or handling machinery during treatment due to potential side effects like dizziness and fatigue.

Side effects:

• Serious: heart problems, allergic reactions, kidney problems, breathing difficulties.
• Common: fever, visual disturbances, nose bleeds or runny nose, hair loss, dizziness, nail disorders, weight loss, loss of appetite, bruising, dry mouth, liver inflammation, muscle pain, asthma/lung disorders.

Warnings:

• Inform your doctor if you have a history of allergic reactions to Hervycta Plus 150mg Injection.
• Monitor heart parameters regularly during treatment.
• Avoid pregnancy and breastfeeding for a minimum of 7 months after the last dose.

FAQs:

• Q1. Is Hervycta Plus 150mg Injection used as a monotherapy in treating breast cancer?
  • Hervycta Plus 150mg Injection is generally given along with chemotherapy medications such as paclitaxel or docetaxel or platinum compounds. Sometimes, it is also given with hormonal agents for those patients with elevated hormonal status.
• Q2. Does Hervycta Plus 150mg Injection cause heart problems?
  • Yes, Hervycta Plus 150mg Injection can damage the heart muscles. Hence, it is advised to do heart check-ups every 3 months and continue until 2-5 years after the treatment completion.
• Q3. Can I breastfeed while on treatment with Hervycta Plus 150mg Injection?
  • No, since it tends to pass into breast milk, it is unsafe to breastfeed. Hence, it is advised not to breastfeed for a minimum of 7 months after the treatment with Hervycta Plus 150mg Injection.
• Q4. Can Hervycta Plus 150mg Injection be consumed during pregnancy?
  • No, it is unsafe to consume Hervycta Plus 150mg Injection while you are pregnant as it can cause harm to the baby.

Fact box:

• Molecule name: Trastuzumab
• Therapeutic class: Anti-cancer
• Pharmacological class: HER2 inhibitor
• Indications:
  • Advanced and metastatic breast cancer
  • Metastatic gastric cancer

Tags: medical-injection, hervycta-plus, pain-relief, anti-inflammatory, pharmaceutical-drug, 440mg